Search PubMed⌕ Search

Biomedical subjects

A Cuomo

Publications and source records attributed to A Cuomo.

At least 37 records · Page 2Linked to original sources
PubMed1998

Antisperm antibodies in cryptorchidism before and after surgery.

PURPOSE: We verified the prevalence of serum antisperm antibodies at diagnosis in a large group of cryptorchid boys, and determined whether it may be influenced by orchiopexy. MATERIALS AND METHODS: We prospectively evaluated serum antisperm antibodies in 186 and 23 boys 0.67 to 14.25 years old with unilateral and bilateral cryptorchidism, respectively, before, and 3, 12 and 24 months after surgery. At diagnosis Tanner stage was 1 and 2 or 3 in 188 and 21 cases, respectively. During the 2-year followup 23 boys entered puberty. A total of 111 normal prepubertal (Tanner stage 1) and 54 pubertal (Tanner stage 2 or 3) boys served as controls. Antisperm antibodies were detected using the tray agglutination and indirect immunobead tests. RESULTS: At diagnosis 29 cryptorchid boys (13.8%) were antisperm antibody positive, including 21 of the 188 prepubertal (11.1%) and 8 of the 21 pubertal (38%) boys (significantly different, chi-square test p <0.001). In 27 cases the tray agglutination test was positive with titers between 1:16 and 1:512, in 18 the indirect immunobead test was positive for IgG with titers between 1:10 and 1:100, and in 16 both tests were positive. There was no statistical difference when antisperm antibody results were analyzed for unilateral and bilateral cryptorchidism or testis location. All normal boys were antisperm antibody negative. During the 2-year followup antisperm antibodies appeared in 1 previously negative case, and the antibody titer increased to 128 to 512 in the tray agglutination and to 1:100 in the indirect immunobead tests in 4 positive cases. In all of these cases pubertal changes were also observed. CONCLUSIONS: Our study indicates that cryptorchidism may elicit an autoimmune response against sperm antigen in childhood independent of testis location and orchiopexy. Moreover, patients of pubertal age appear to be at higher risk for antisperm antibody development.

Adolescent↗
PubMed1997

Inhaled beclomethasone dipropionate downregulates CD4 and CD8 T-lymphocyte activation in peripheral blood of patients with asthma.

BACKGROUND: Previous studies demonstrated a downregulation of T-lymphocyte (CD3+ cells) activation in peripheral blood after treatment with inhaled corticosteroids in patients with asthma. OBJECTIVE: This study was carried out to evaluate the effect of inhaled corticosteroids on CD4 and CD8 T-lymphocyte activation, respectively. METHODS: We examined the expression of three surface activation markers (CD25, HLA-DR, and very late activation antigen 1) on circulating CD4+ and CD8+ T-cell subsets in subjects with asthma (n = 23) before and 8 weeks after treatment with inhaled beclomethasone dipropionate dry powder (daily dose, 800 microg). RESULTS: Beclomethasone dipropionate treatment had a marked effect in reducing the expression of the activation marker CD25 (p < 0.01) in both CD4+ and CD8+ T-cell subsets in peripheral blood of patients with asthma. However, no correlation was found between the downregulation of CD4 and CD8 T-lymphocyte activation and the improvement in physiologic indices of disease activity. CONCLUSIONS: These data add to the view that CD4+ and CD8+ T lymphocytes in peripheral blood of patients with asthma are in an activated state that is downregulated by inhaled corticosteroids.

Administration, Inhalation↗
PubMed1997

Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy.

One of the possible drawbacks to autologous stem cell transplantation in breast cancer (BC) patients is the potential for tumor contamination in the transplanted product. We present a patient with advanced disease who received high-dose chemotherapy (HDC) and PBPC support as consolidation therapy after achieving complete remission with standard-dose first-line treatment, and suffered recurrence of the disease 6 months after transplantation. Retrospective analysis revealed the presence of contaminating cells in the leukapheretic product, and clinical evidence suggested a role for these cells in the tumor relapse.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1991

Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies.

In 16 patients with monoclonal gammopathies of undetermined significance (MGUS) and in 49 with multiple myeloma (MM, 43 untreated and 6 relapsed) we used immunocytochemistry to determine the percentages of bone marrow plasma cells (BMPC) that incorporate bromodeoxyuridine (BUDR-labeling index, BUDR-LI) in vitro and that label with the monoclonal antibody Ki-67 (which recognizes an antigen thought to identify the growth fraction of the population, Ki-67 GF). Both mean and range values were greater for Ki-67 GF than for BUDR-LI. Most patients with high Ki-67 GF also had high BUDR-LI, although a linear correlation was not found between the two parameters. MGUS has lower values than MM, and the difference was much greater for Ki-67 GF than for BUDR-LI (p less than 0.005 vs. p less than 0.05). Differences in Ki-67 GF but not in BUDR-LI were found between MGUS and stage I MM (p less than 0.0005) and between grouped stage I and II MM and stage III MM (p less than 0.025). Both Ki-67 GF and BUDR-LI were significantly (p less than 0.005) greater in relapsed than in untreated MM. Determining Ki-67 GF as a proliferative parameter could be a better way of studying the kinetics of (BMPC) in MGUS and MM than determining the BUDR-LI, since a wider range of values is obtained and this allows patient groups with different clinical characteristics to be separated more easily.

Biomarkers↗
PubMed1990

Immunocytochemical evaluation of proliferative activity in human brain tumours.

The immunocytochemical expression of the antigen reacting with the monoclonal antibody Ki-67 (Ki-67 positivity) was investigated in 50 imprint preparations from human brain tumours. Data were related to tumour proliferative activity, as determined from in vivo bromodeoxyuridine (BrdU) incorporation (BrdU-labelling index, BrdU-LI) and histology. The percentage of Ki-67-positive cells was greater than the corresponding BrdU-LI value in all tumours, and the differences in Ki-67 positivity among tumour subtypes paralleled the BrdU-LI differences. Both the BrdU-LI and the percentage of Ki-67 positive cells were significantly greater (P less than 0.005) in the group of clinically aggressive adult tumours, histologically identified as anaplastic astrocytomas and glioblastomas, than in the less aggressive ones (oligodendroglioma, meningiomas, schwannomas, pituitary adenomas, dermoid cyst) and in the cerebral metastatic localizations. These data suggest that Ki-67 positivity, which is easily evaluated with immunocytochemistry, is related to the proliferative activity of brain tumours and that this parameter is endowed with clinical significance.

Antibodies, Monoclonal↗
PubMed1988

Early bronchodilating effect of a new oral beta-2-receptor agonist (broxaterol) in bronchial asthma.

In order to determine the bronchodilating activity and safety of two beta-2-receptor agonists, broxaterol and procaterol, compared with a placebo, 12 patients with reversible airway obstruction were tested in a double-blind cross-over study. The drugs were administered orally and the dosage of broxaterol was 0.5 mg, that of procaterol 0.05 mg. Measurements of forced expiratory volume in 1 s (FEV1), heart rate and blood pressure were performed before and 30, 60, 120, 240, 360, and 480 min after each treatment. Both drugs produced bronchodilation but broxaterol was statistically 30 min faster in producing this effect than procaterol (p less than 0.05). Moreover this effect for both drugs persisted significantly for up to 480 min compared with the effect of the placebo (p less than 0.005). There were no significant side effects with either drug. Heart rate and blood pressure did not show any changes in clinical significance for broxaterol or procaterol. In our study, broxaterol showed a faster bronchodilating effect than procaterol, and tolerance was the same for both drugs.

Administration, Oral↗
PubMed1988

Evaluation of bronchial responsiveness by pharmacological challenges in asthma. Inhaled propranolol in comparison with histamine and methacholine.

Bronchial challenges with bronchoconstrictive drugs have supplied important information on some relevant pathophysiological aspects of bronchial asthma, i.e. nonspecific bronchial hyperresponsiveness. Until now histamine and methacholine have been the most widely used inhalation tests. Recently, propranolol, given by inhalation, has been proposed and evaluated for possible application as a bronchial provocation challenge both in clinical and experimental setting. In asthmatic subjects with bronchial hyperresponsiveness to histamine and methacholine, inhaled propranolol induces a dose-related bronchoconstriction. In a group of 25 asthmatic patients, the mean value of provocative doses, in mumoles of propranolol that causes a 20% drop in FEV1 (PD20FEV1), is thirteen times greater than that of methacholine. In the same study, there is no correlation between the bronchial responses to the two drugs. Moreover, none of 9 normal subjects of the control group responds to inhaled propranolol. The mechanisms of propranolol-induced bronchoconstriction are poorly understood. A cholinergic reflex is probably involved, but it is likely that propranolol has some different and rather peculiar pathways. Bronchial response to inhaled propranolol is a reliable, reproducible, safe, and well-tolerated method. Bronchoconstriction induced by propranolol appears to be a very promising technique in the investigation of the mechanisms of nonspecific bronchial hyperresponsiveness.

Adolescent↗
PubMed1987

Provocative dose and dose-response curve to inhaled propranolol in asthmatic patients with bronchial hyperresponsiveness to methacholine.

This study was carried out to compare bronchial responses to inhaled propranolol (P) and methacholine (M) in a group of asthmatic subjects with mild to moderate bronchial hyperresponsiveness to M; to determine the short term reproducibility of bronchial response to propranolol; and to examine the shape of dose-response curve to P relative to that of M. Doses of M and P were given in mumoles and bronchial responses to both agents were expressed as the provocative dose that induced a 20 percent fall in FEV1 (PD20 FEV1). In 16 asthmatic patients, there was no correlation between the PD20 of the two agents. Mean PD20 M (+/- SD in log scale) was approximately nine times lower than mean PD20 P (0.64 +/- 0.96 and 5.80 +/- 1.65, respectively). This difference was statistically significant (t = 4.58, p less than 0.001). In six asthmatic patients, the reproducibility of PD20 P was similar to that of M (intraclass correlation coefficient 0.969 and 0.957, respectively). The shape of the dose-response curves to P was different from that of M in five of nine asthmatic patients when all experimental points were analyzed by double-reciprocal plot. We noticed that even small doses of inhaled P may cause a severe bronchoconstriction. Therefore, special caution should be taken to increase P doses very gradually, when studying the dose-response curve. We demonstrated that P inhalation induced a measurable bronchoconstriction in subjects with mild to moderate hyperresponsiveness and it was reproducible. However, the bronchial sensitivity to P was lower than to M. Our findings suggest that P and M have different mechanisms of action.

Asthma↗
PubMed1983

[Comparative study of pre and post-operative dynamic respiratory indices in subjects undergoing total laryngectomy].

A spirometric measurement was carried out on patients with cancer of the laryn before and after surgery for total laryngectomy at the Istituto Policattedra of the University of Parma ENT Clinic. Postoperative spirometry was performed by means of a Vitalograph apparatus with the mouthpiece positioned right over the tracheal opening. The parameters considered were the dynamic respiratory indices (CV/MEVS - MEVS/CV). Forty patients was mostly based on the fact that, prior to laringectomy, all of them had been subjected to a spirometric measurement for aneasthesiologic purposes. According to the results obtained, the patients can be divided into three groups. The first group consists of 10 subjects in whom no improvement was observed in their MEVS value, which in some instances had actually worsened. The second group is composed of 20 patients in whom the spirometric values remained more or less steady. The third group comprises 20 patients who showed a marked improvement of their respiratory indices. In some of the latter patients the values obtained were even better than those in the normal range. However, the overall average results are not statistically significant, except for an average 9% improvement of MEVS due, as expected, to a reduction of the dead space following total laryngectomy and a corresponding, though very slight, 4% improvement of the Tiffenau ratio.

Aged↗
PubMed1978

[Lung blood perfusion changes following tubercular processes cured by antibiotic drug therapy].

This is a studym ade by pulmonary perfusional scintigraphy and angiopneumography on 60 patients suffering from tuberculosis of the lung; they were cured by chemoantibiotic treatment. They were recent tubercular diseases with limited extension (nodular infiltrations, former phthisiogenic lobitises, nodular and miliarich disseminations), so their outcomes were extremely modest or not worthy on radiologic plane. The results acquired with these methods firmly showed a larger ematoperfusive injury as to the affected area.

Adult↗